Stoke Therapeutics, Inc. cash flow to debt ratio of 1.52K% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Stoke Therapeutics, Inc.'s free cash flow has increased -151.59% from $-87.05M last year to $44.91M, signaling increasing performance

Stoke Therapeutics, Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.

Stoke Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.02 last year to 0.01 today, signaling strengthened financials

Stoke Therapeutics, Inc. has a net cash position, so leverage is healthy.

Stoke Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Stoke Therapeutics, Inc.'s profit margin has decreased (209.59%) in the last year from -243.42% to -753.60%, signaling decreasing performance

Stoke Therapeutics, Inc.'s short-term assets of $305.70M exceed its short-term liabilities of $57.88M

Stoke Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Stoke Therapeutics, Inc.'s return on equity of -59.36%, is lower than 15.00%, indicating bad performance

Stoke Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Stoke Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Stoke Therapeutics, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Stoke Therapeutics, Inc. has a free cash flow yield of 2.16%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Stoke Therapeutics, Inc.'s yearly earnings has increased -92.26% since last year from $-88.98M to $-6.88M, signaling increasing performance

Stoke Therapeutics, Inc.'s yearly revenue has increased 404.50% since last year from $36.55M to $184.42M, signaling increasing performance

ROIC -62.74% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Stoke Therapeutics, Inc.'s 3-year revenue CAGR of 145.89% is positive, indicating growing revenue over the past 3 years

Stoke Therapeutics, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Stoke Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Stoke Therapeutics, Inc. has insufficient data to evaluate this check.

Stoke Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Stoke Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Stoke Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Stoke Therapeutics, Inc. has insufficient data to evaluate this check.

Stoke Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Stoke Therapeutics, Inc. has a price-to-book ratio of 6.16x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Stoke Therapeutics, Inc. has a price-to-sales ratio of 77.12x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue